RxDoctor Payments Data

Fredrick Odongo

Psychiatric/Mental Health · Arlington, TXNPI 1104582006

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $27,192 of the $39,095 with a category attached, or 69.6%. Neurocrine Biosciences, Inc. accounts for 97.7% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $38,162, more than ten times the $240 reported in 2022. Among psychiatric/mental health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$39,095in general payments, 2019–2025

Across 93 payments — averaging $420.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$38K
  • Johnson & Johnson$330
  • Teva Pharmaceuticals USA, Inc.$272
  • Otsuka America Pharmaceutical, Inc.$121
  • Alkermes, Inc.$87
  • Acadia Pharmaceuticals Inc$55
  • plus $42 from 2 others

What the payments were for

  • Consulting fees$6,18816%
  • Speaking & faculty fees$27,19270%
  • Travel & lodging$3,4689%
  • Food & beverage$2,1365%
  • Education$1110%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,095 in reported general payments places this provider in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$245,556
Medicare patients
350
Services billed
2,673

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate60$254,001
Divalproex Sodium668$32,379
Duloxetine Hcl430$14,451
Buspirone Hcl526$9,073
GemtesaVibegron21$4,939
Trazodone Hcl513$4,353
Escitalopram Oxalate320$3,839
Hydroxyzine Hcl206$3,640
Fluoxetine Hcl193$3,619
Sertraline Hcl310$2,991
Mirtazapine135$2,854
Quetiapine Fumarate97$2,745
Donepezil Hcl89$2,528
BelsomraSuvorexant12$1,929
Memantine Hcl40$1,612

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$38,188$254,00160 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Arlington

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →